Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.
Metrics to compare | 9887 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9887PeersSector | |
---|---|---|---|---|
P/E Ratio | −39.7x | −37.0x | −0.7x | |
PEG Ratio | - | −0.45 | 0.00 | |
Price/Book | 108.6x | 6.3x | 2.6x | |
Price / LTM Sales | - | 19.2x | 3.4x | |
Upside (Analyst Target) | 24.6% | 38.3% | 38.2% | |
Fair Value Upside | Unlock | −13.9% | 4.6% | Unlock |